PSLNR

From LncRNAWiki
Revision as of 06:42, 28 January 2021 by Chang Liu (talk | contribs) (Created page with "PSLNR may be a candidate diagnosis and therapeutic target for PCa.<ref name="ref1" /> ==Annotated Information== ===Name===...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

PSLNR may be a candidate diagnosis and therapeutic target for PCa.[1]

Annotated Information

Name

Approved symbol:PSLNR

Approved name:prostate enriched lncRNA

HGNC ID HGNC:54405

Alias symbol:LA16c-83F12.6

RefSeq ID:NR_132385

Characteristics

Please input information here.[1]

Function

PSLNR inhibited PCa progression via the p53-dependent pathway.[1]

Regulation

PSLNR also significantly inhibited PCa proliferation by inducing cell apoptosis in a p53-dependent manner.[1]

Expression

PSLNR was specifically expressed in the prostate.[1]

Diseases

Prostate cancer (PCa)[1]

Labs working on this lncRNA

  • State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, School of Life Science, Fudan University, Shanghai, PR China.[1]
  • Department of Urology, Shanghai Four People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, PR China.[1]

References

[1](1)

</references>
  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Wang D, Wan X, Zhang Y, Kong Z, Lu Y, Sun X, Huang Y, Ji C, Li D, Luo J, Gu W, Wang C, Li Y, Xu Y. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway. Prostate. 2019 Sep;79(12):1362-1377. doi: 10.1002/pros.23840. Epub 2019 Jul 3.